CUBT (Curative Biotechnology) ROCE %: 0.00% (As of Mar. 2023)


What is Curative Biotechnology ROCE %?

Curative Biotechnology CUBT +17.98% ROCE % is 0.00% as of Mar. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Curative Biotechnology's annualized ROCE % for the quarter that ended in Mar. 2023 was 0.00%.

Curative Biotechnology  (OTCPK:CUBT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Curative Biotechnology ROCE % Related Terms

Curative Biotechnology ROCE % Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology ROCE % Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial 0.00 0.00 -740.58 -313.83 0.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -336.95 -526.23 0.00 0.00 0.00

Curative Biotechnology ROCE % Calculation

Curative Biotechnology's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-4.435/( ( (2.412 - 0.73) + (2.089 - 4.487) )/ 2 )
=-4.435/( (1.682+-2.398)/ 2 )
=-4.435/-0.358
=1,238.83 %

Curative Biotechnology's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=-2.62/( ( (2.089 - 4.487) + (2.132 - 5.332) )/ 2 )
=-2.62/( ( -2.398 + -3.2 )/ 2 )
=-2.62/-2.799
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Curative Biotechnology (CUBT) has a ROCE % of 0.00% as of Mar. 2023.
Is Curative Biotechnology's ROCE % too high?
Curative Biotechnology's current ROCE % is 0.00%.
How does Curative Biotechnology's ROCE % compare to ORGS and SNSE?
Curative Biotechnology's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Curative Biotechnology's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current ROCE % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.